PEPTIDE CORTEXThe library
← The library

Semaglutide

Wegovy/OzempicMetabolic/Weight
Evidence grade
AFDA-approved Rx (labeled use)
Cardiovascular · 0–5 · separate axis
5
Read first · not dosing instructions

Educational and research reference only. Not medical advice, not a recommendation, and not dosing instructions for any person. Figures are reported from the cited source and may be wrong or out of date. Research peptides are not approved for human use. Adults 18+. Consult a licensed physician before any decision about your health.

PurposeMetabolic / Weight loss
MechanismGLP-1 receptor agonist: increases satiety, slows gastric emptying, improves insulin secretion
EffectsLess hunger, slower digestion, better blood sugar; often improves BP and overall CV risk
DosingInjection: 0.25 mg weekly, stepped up every 4 weeks through 0.5, 1 and 1.7 mg to a maintenance of 1.7 or 2.4 mg weekly; maximum 7.2 mg weekly for adults who have tolerated 2.4 mg for at least 4 weeks (Wegovy, label 06/2026). Wegovy tablets: 1.5 mg, then 4 mg, then 9 mg, then 25 mg once daily, in 30-day steps.
Bottom lineStrongest data when used for its labeled indication under clinician guidance.
Protocols · as published4 sourced
FDA labelWegovy injection (label revised 06/2026)
RouteSubcutaneous injection
FrequencyOnce weekly
Starting0.25 mg once weekly, weeks 1-4
Escalation0.5 mg weeks 5-8, 1 mg weeks 9-12, 1.7 mg weeks 13-16. If a dose is not tolerated during escalation, consider delaying escalation for 4 weeks.
TargetAdult weight reduction: 1.7 mg or 2.4 mg (recommended) once weekly
Maximum7.2 mg once weekly (adult weight reduction only, after tolerating 2.4 mg for at least 4 weeks, when additional weight reduction is clinically indicated; supplied as Wegovy HD 7.2 mg/0.75 mL)

If 2 or more consecutive doses are missed, the label says to reinitiate escalation at a lower dosage. Escalation exists "to reduce the risk of gastrointestinal adverse reactions".

FDA labelWegovy tablets (label revised 06/2026)
RouteOral tablet
FrequencyOnce daily, on an empty stomach with up to 4 oz water, then wait 30 minutes before food or other drinks
Starting1.5 mg once daily, days 1-30
Escalation4 mg once daily days 31-60, 9 mg once daily days 61-90
Target25 mg once daily (maintenance), from day 91
FDA labelOzempic injection (type 2 diabetes)
RouteSubcutaneous injection
FrequencyOnce weekly
Starting0.25 mg once weekly for 4 weeks (initiation only, not effective for glycemic control)
Escalation0.5 mg once weekly; after at least 4 weeks on 0.5 mg, may go to 1 mg; after at least 4 weeks on 1 mg, to 2 mg
Target0.5 mg, 1 mg or 2 mg once weekly
Maximum2 mg once weekly

Taken from search-result extracts of the label, not a line-by-line read of the PDF.

Community protocol — not clinically establishedCommunity guide
RouteSubcutaneous injection
FrequencyOnce weekly
Starting0.25 mg weekly, described as "Starting dose for tolerability only. Not a therapeutic dose."
Escalation0.25 then 0.5, 1.0, 1.7 and 2.4 mg, 4 weeks per step, with the option to delay
Target2.4 mg weekly (the page does not mention the 7.2 mg label dose)
CycleAbout 16 weeks to reach maintenance, then ongoing
Batches on file2
10 mgJA-58538 · 2025-0399.75%
20 mgJA-63067 · 2025-0499.57%
Read with10
Cautions & interactions

GI side effects; risk of pancreatitis; gallbladder disease; contraindicated in MTC/MEN2 history

Caution with insulin/sulfonylureas (hypoglycemia risk); delays gastric emptying may affect absorption of oral meds; monitor for dehydration if on diuretics.

CV 5 of 5 — Strong human outcomes data via diabetes/obesity trials; improves multiple CV risk factors (weight, glucose, BP).